While the public advisory committee meetings convened in 2024 resulted in the PCAC voting against inclusion of all previous peptides under review, finding that they posed unacceptable safety risks for compounding, whether the current regulatory and political environment will produce a different outcome at the July meeting remains to be seen
Novel drugs approved by the EMA, FDA, and MHRA in 2023
Community estimates suggest approximately 60% better results compared to either peptide alone, though controlled studies confirming this figure do not exist
Add 100 L DTNB Reagent to all tubes
drug approval, and the compound's legal status has only become more restrictive over time
Previous research has shown that GPx1 is an effective antioxidant enzyme that cannot be replaced by any other selenoprotein to protect against generalized oxidative stress [74,75,76]